Health Care Originals

About the offering

Health Care Originals (HCO) is a Rochester, NY-based healthtech company developing AI-powered wearables and virtual therapy programs for people living with chronic conditions. The company currently operates two programs: HCO Respiratory, which uses a commercially deployed wearable device called ADAMM to continuously monitor patients with asthma and COPD and detect early warning signals before a crisis occurs; and HCO Neuro, which uses a prototype robotic glove called Imago Assist to help stroke survivors regain hand mobility through virtual therapy sessions. Both programs are powered by Aidah, HCO's proprietary AI intelligence layer, which is trained on millions of physiological readings and personalizes care at the individual level rather than relying on population averages. Three University of Rochester studies reportedly show HCO data can predict emergency or hospital care needs up to three months in advance. HCO has raised $12M to date from venture investors including Safar Partners (lead), Chloe Capital, Kingscrowd Capital, and D3VC.ai. The company reports 8x revenue growth in HCO Respiratory and 7.5x revenue growth in HCO Neuro since its last funding round, with a target of $12M ARR run rate by Q4 2027 (not guaranteed). HCO Neuro is covered by 36 insurers across 13 states, and the company has a $129M ARR pipeline for Respiratory Care representing talks with health plans covering 5,000,000 lives, plus a potential MSSP federal program contract covering 200,000 Medicare patients. HCO holds 41 patents issued and pending, including 2 AI patents, and has two AI agents deployed. The company operates on an outcomes-based revenue model where payer revenue rises as members require less care, and it earns a percentage of savings generated. HCO has also formalized an agreement to acquire a majority stake in Imago Rehab, which now forms the basis of HCO Neuro. Future expansion plans include a speech therapy AI product called ReSpeak (alpha launch planned December 2026) and a cardiology offering leveraging existing wearable hardware. The long-term strategy involves growing each condition-specific program to a revenue threshold, then spinning each out as an independent company while HCO retains a stake. The founding team includes CEO Sharon Samjitsingh (personal asthma history, engineering and entrepreneurship background, 7 patents), COO Jared Dwarika (20 years device sales and manufacturing, 14+ patents), and Chief Medical Officer Jennifer Chambers (MD MBA, ex-Medical Director at Capital Blue Cross). The company is raising $4.5M in its current round, with $450,000 allocated to a community offering on Wefunder. Lead investor Safar Partners has committed the first $1.5M. HCO is featured in Forbes, USA Today, and Masters of Scale, and is a PurposeBuilt100 honoree.

FAQ